Johnson & Johnson has announced its Tecnis PureSee intraocular lens (IOL) has been implanted in 100,000 eyes across Australia and New Zealand since its regional introduction in mid 2024.
PureSee is a refractive extended depth of focus lens designed to provide distance and intermediate vision, with some near vision. It sits within the broader Tecnis portfolio, which also includes monofocal, enhanced monofocal, and full vision range lenses.
Johnson & Johnson said the range gives surgeons options to address patients’ visual needs following cataract surgery, including their use of digital devices and desire to reduce dependence on glasses.
The company also cited its preloaded delivery system and a consistent A-constant across the Tecnis one-piece lens range as features intended to simplify surgical planning and workflow.
Johnson & Johnson said the range gives surgeons options to address patients’ visual needs following cataract surgery, including their use of digital devices and desire to reduce dependence on glasses.
Blake Thomas, Johnson & Johnson MedTech’s country manager for surgical vision in Australia and New Zealand, thanked surgeons and practice teams for their role in reaching the milestone. He said technologies such as PureSee could “provide surgeons with additional options to support the visual and lifestyle needs of their patients at the time of cataract surgery”.
Johnson & Johnson said the rapid uptake of Tecnis PureSee IOL across Australia and New Zealand “reflects the confidence ophthalmologists place in this technology to consistently provide favourable patient outcomes including high clarity vision across high and low light situations”.
The company introduced Tecnis Eyhance, an enhanced monofocal lens, in the region in 2019, before adding PureSee in 2024.
